COMPARISON OF INTRON A + S-P AND ICN RIBAVIRIN CAPSULES IN CHRONIC HEPATITIS C

内含子A S-P与ICN利巴韦林胶囊治疗慢性丙型肝炎的比较

• 批准号: 6118131
• 负责人: John G. McHutchison
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6118131
• 关键词: chronic disease /disorder; clinical research; clinical trials; combination chemotherapy; dosage forms; drug screening /evaluation; hepatitis C; human subject; human therapy evaluation; immunotherapy; interferon alpha; liver disorder chemotherapy; pharmacokinetics; ribavirin

The primary objective of this study is to compare the multiple dose bioavailability of ICN and Schering-Plough ribavirin capsules in compensated chronic hepatitis C in conjunction with interferon alpha-2b. The secondary objective is to assess patient variability with regard to pharmacokinetics of each ribavirin capsule formulation. This clinical trial continues and no preliminary results are available.

本研究的主要目的是比较ICN和先灵葆雅利巴韦林胶囊联合干扰素α-2b治疗代偿性慢性丙型肝炎的多剂量生物利用度。次要目的是评估每种利巴韦林胶囊制剂的药代动力学的患者变异性。 该临床试验仍在继续，目前尚无初步结果。